Kevin Snyder recently served at FDA/CDER as the Associate Director of Nonclinical Informatics, where he managed data science and informatics initiatives to support the pharmacology/toxicology review program. These initiatives included research efforts to develop methods to optimize the regulatory use of standardized electronic CDISC-SEND-formatted toxicology study data as well as internal informatics projects to promote the development of scientifically sound, data-driven regulatory policies. Kevin has joined Certara in a new role as Director of Nonclinical Innovation and Emerging Technologies, guiding pharmaceutical sponsors in their efforts to strategically integrate nonclinical data across all phases of pharmaceutical development and enhance new drug safety. Prior to this transition, Dr. Snyder had served in various roles at the FDA: first in CDRH as a bioinformatician and in vitro diagnostic device reviewer and then as pharmacology/toxicology reviewer in CDER. He has played a leading role in several precompetitive consortia, including the Pistoia Alliance, CDISC, PHUSE, VICT3R, and BioCelerate, supporting efforts to enhance the implementation and utilization of standardized toxicology study data. Kevin is a dedicated advocate for the modernization of regulatory toxicology via strategic adoption of data standards and data science techniques to drive innovation in areas such as predictive modeling, virtual controls, and new approach methodologies (NAMs).